Durrant I J, Prentice H G, Richards S M
Br J Haematol. 1997 Oct;99(1):84-92. doi: 10.1046/j.1365-2141.1997.3613175.x.
The MRC UKALL XA trial for patients aged 15 years and over with acute lymphoblastic leukaemia was designed to evaluate short blocks of intensive 'AML-style' treatment. Between 1985 and 1992, 618 eligible patients were entered into the trial. 450 patients were randomized to receive early intensification at 5 weeks, late intensification at 20 weeks, both, or neither. Unlike the concurrent children's trial, UKALL X, which was of similar design, UKALL XA does not demonstrate a clear benefit for intensification, although there was a significant reduction in the relapse risk due to the early block. The estimated increase in disease-free survival at 5 years was 2% with 95% confidence interval from 1% reduction to 5% increase. There may be a real difference between the effect of these treatments in adults and in children, but this result may be somewhat weakened by poorer compliance, with a greater proportion of adults not receiving the treatment arm to which they were randomized.
英国医学研究委员会（MRC）针对15岁及以上急性淋巴细胞白血病患者开展的UKALL XA试验旨在评估短期强化“急性髓系白血病（AML）式”治疗。1985年至1992年间，618名符合条件的患者进入该试验。450名患者被随机分组，分别接受5周时的早期强化治疗、20周时的晚期强化治疗、两者都接受或两者都不接受。与设计类似的同期儿童试验UKALL X不同，UKALL XA并未显示出强化治疗有明显益处，尽管早期强化治疗使复发风险显著降低。5年时无病生存率的估计增幅为2%，95%置信区间为降低1%至增加5%。这些治疗方法在成人和儿童中的效果可能存在实际差异，但由于依从性较差，这一结果可能会有所减弱，因为有更大比例的成人未接受其随机分配的治疗组。
